Inflammatix
Molecular diagnostics company developing rapid, sample-to-answer host-response tests and a cartridge-based point-of-care instrument to distinguish bacterial vs viral infection and to prognose illness severity (risk of progression to critical care). Combines multi-gene mRNA measurements, isothermal and PCR assay translation, and machine-learning classifiers. Work includes analytical and clinical validation across multi-cohort datasets, regulatory submissions, and partnerships with public health agencies.
Industries
Nr. of Employees
medium (51-250)
Inflammatix
Patents
DNA sequences related to diagnosis and treatment of systemic inflammatory response syndrome
US-11104946-B2
View DetailsSystems and methods for transmitting pathogen related information and responding
US-8068991-B2
View Details
DNA sequences related to diagnosis and treatment of systemic inflammatory response syndrome
US-11104946-B2
View DetailsSystems and methods for transmitting pathogen related information and responding
US-8068991-B2
View DetailsProducts
TriVerity test
Rapid diagnostic and prognostic host-gene-expression test that provides probabilistic scores for bacterial infection, viral infection, and all-cause illness severity to support triage decisions.
HostDx Sepsis and HostDx Fever tests
Host-response tests that measure expression levels of selected immune genes to identify bacterial vs viral infection and to assess sepsis risk; intended for rapid use in hospital and outpatient settings.
Point-of-care instrument (Myrna instrument referenced in analytical evaluations)
Cartridge-based instrument platform intended to run host-response assays with rapid isothermal chemistry (RT-LAMP) and provide sample-to-answer results in near-patient settings.
Myrna platform
A point-of-care instrument in development to quantify InSep's 29 mRNAs using LAMP with a turnaround time of less than 30 minutes, designed for automated operation with minimal hands-on time.
Myrna Instrument
A proprietary, cartridge-based, benchtop analyzer capable of multiplex sample-to-answer quantitation of mRNAs in about 30 minutes, with less than one-minute operator hands-on time and simple maintenance, designed for ease of use and low resource requirements.
HostDx
A multiplex quantitative gene expression test for rapid diagnosis of sepsis with a turnaround time of approximately 60 minutes. It provides a sample-to-answer solution with moderate complexity and is developed through device/manufacturing partnerships.
TriVerity test
Rapid diagnostic and prognostic host-gene-expression test that provides probabilistic scores for bacterial infection, viral infection, and all-cause illness severity to support triage decisions.
HostDx Sepsis and HostDx Fever tests
Host-response tests that measure expression levels of selected immune genes to identify bacterial vs viral infection and to assess sepsis risk; intended for rapid use in hospital and outpatient settings.
Point-of-care instrument (Myrna instrument referenced in analytical evaluations)
Cartridge-based instrument platform intended to run host-response assays with rapid isothermal chemistry (RT-LAMP) and provide sample-to-answer results in near-patient settings.
Myrna platform
A point-of-care instrument in development to quantify InSep's 29 mRNAs using LAMP with a turnaround time of less than 30 minutes, designed for automated operation with minimal hands-on time.
Myrna Instrument
A proprietary, cartridge-based, benchtop analyzer capable of multiplex sample-to-answer quantitation of mRNAs in about 30 minutes, with less than one-minute operator hands-on time and simple maintenance, designed for ease of use and low resource requirements.
HostDx
A multiplex quantitative gene expression test for rapid diagnosis of sepsis with a turnaround time of approximately 60 minutes. It provides a sample-to-answer solution with moderate complexity and is developed through device/manufacturing partnerships.
Services
Design and conduct of multi-cohort analytical and clinical validation studies for host-response diagnostic signatures and instrument performance.
Translation of multi-gene host-response assays onto rapid cartridge-based instruments suitable for ED, urgent care, and outpatient settings.
Design and conduct of multi-cohort analytical and clinical validation studies for host-response diagnostic signatures and instrument performance.
Translation of multi-gene host-response assays onto rapid cartridge-based instruments suitable for ED, urgent care, and outpatient settings.
Expertise Areas
- Host-response diagnostics (blood transcriptomics)
- Machine-learning for diagnostic classifiers
- Point-of-care and near-patient test development
- Molecular assay translation (isothermal and PCR)
Key Technologies
- mRNA host-response panels
- Isothermal amplification (RT-LAMP)
- Multiplex PCR (TaqMan-style assays)
- Cartridge-based sample-to-answer instruments
News & Updates
FDA clearance obtained for a rapid diagnostic and prognostic host-gene-expression test intended to support triage decisions in acute care settings.
Cost-sharing contract with BARDA to advance development and commercialization of HostDx point-of-care tests, with initial funding and milestone-based total potential support.
Raised $32 million in Series C financing to advance rapid HostDx tests toward commercial launch in Europe and regulatory submission in the U.S.
Received AACC Disruptive Technology Award for rapid host-response diagnostic tests presented at the AACC Annual Scientific Meeting.
Peer-reviewed analytical evaluation reporting performance of a rapid diagnostic and prognostic host gene-expression test performed on the company instrument using RT-LAMP.
Publication reporting a locked 29-mRNA neural-network classifier for acute bacterial and viral infections validated across >1,000 samples and independent cohorts.
FDA clearance obtained for a rapid diagnostic and prognostic host-gene-expression test intended to support triage decisions in acute care settings.
Cost-sharing contract with BARDA to advance development and commercialization of HostDx point-of-care tests, with initial funding and milestone-based total potential support.
Raised $32 million in Series C financing to advance rapid HostDx tests toward commercial launch in Europe and regulatory submission in the U.S.
Received AACC Disruptive Technology Award for rapid host-response diagnostic tests presented at the AACC Annual Scientific Meeting.
Peer-reviewed analytical evaluation reporting performance of a rapid diagnostic and prognostic host gene-expression test performed on the company instrument using RT-LAMP.
Publication reporting a locked 29-mRNA neural-network classifier for acute bacterial and viral infections validated across >1,000 samples and independent cohorts.